Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
DCOY
DECOY THERAPEUTICS INC.
NASDAQ
$2.78
▼ DOWN 1.77% (-0.05)

KEY STATISTICS

Market Cap$1.48 M
52w High$55.92
52w Low$2.59
Dividend Yield—
Frequency—
P/E-0.02
Volume28.52K
Shares Out.531.97K

COMPANY

LEADERSHIP

Frederick E. Pierce
CHIEF EXECUTIVE
Frederick E. Pierce

COMPENSATION 2026

Salary$176,153
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$550,032
Total$734,450

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 29, 2015
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
11

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.—
NOV
13
FRI

SPLIT RECORD

DATETYPERATIO
2026-03-09Reverse1:12
2025-08-18Reverse1:15
2024-06-17Reverse1:8
2022-10-17Reverse1:25
2019-07-22Reverse1:25

PRICE

$2.78 ▼ DOWN 1.77% (−$0.05)
OVERLAYS
$2.80$2.85$2.909:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.78

About Decoy Therapeutics Inc.

https://decoytx.com ↗

Decoy Therapeutics, Inc., a Cambridge-based preclinical biotech, uses AI, machine learning, and rapid synthesis to design and develop peptide conjugate drugs for serious unmet medical needs.

INDUSTRY

Biotechnology

A SERVICE DECOY THERAPEUTICS INC. IS KNOWN FOR

IMP3ACT Platform and Lead Pan-Coronavirus Antiviral Candidate

Decoy Therapeutics is a preclinical biotech using AI-driven IMP3ACT platform to develop peptide conjugate drugs, including a leading intranasal pan-coronavirus antiviral candidate.

COMPETITORS

COMPETITOR
ALGS COMPARE
COCP COMPARE
GILD COMPARE
PFE COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
2
LISTED HERE
2
RANKED BY POSITION SIZE
VXF
0.00% · 4.0K
MEDX
0.00% · 20

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR
Lieber Jonathan I
Purchase · 2.0K shares
2026-08-31
★
OFFICER: CHIEF EXECUTIVE OFFICER
PIERCE FREDERICK II
Purchase · 33.5K shares
2026-08-31
★
OFFICER: CHIEF BUSINESS OFFICER
Marschel Peter Klaus
Purchase · 3.9K shares
2026-08-31
★
OFFICER: CHIEF FINANCIAL OFFICER
Rosenblum Mark J
Purchase · 9.7K shares
2026-08-31

SECTORS PEERS

PEERPRICE
INDP$3.55COMPARE
GTBP$7.16COMPARE
REVB$0.93COMPARE
ATXI$0.48COMPARE
ENVB$1.62COMPARE
NKGN$0.00COMPARE
SPRC$4.51COMPARE
SLXN$0.44COMPARE